Global Varicella Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

According to APO Research, The global Varicella Attenuated Live Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Varicella Attenuated Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Varicella Attenuated Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Varicella Attenuated Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Varicella Attenuated Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Varicella Attenuated Live Vaccine include Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech and Changchun Changsheng Life Sciences Limited, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Varicella Attenuated Live Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Varicella Attenuated Live Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Varicella Attenuated Live Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Varicella Attenuated Live Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Varicella Attenuated Live Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Varicella Attenuated Live Vaccine sales, projected growth trends, production technology, application and end-user industry.

Varicella Attenuated Live Vaccine Segment by Company

Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited

Varicella Attenuated Live Vaccine Segment by Type

Monovalent Vaccine
Combination Vaccine

Varicella Attenuated Live Vaccine Segment by Application

Kids Injection
Adults Injection

Varicella Attenuated Live Vaccine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Varicella Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Attenuated Live Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Attenuated Live Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Varicella Attenuated Live Vaccine Market Size, 2020 VS 2024 VS 2031
1.3 Global Varicella Attenuated Live Vaccine Market Size Estimates and Forecasts (2020-2031)
1.4 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts (2020-2031)
1.5 Global Varicella Attenuated Live Vaccine Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Varicella Attenuated Live Vaccine Market Dynamics
2.1 Varicella Attenuated Live Vaccine Industry Trends
2.2 Varicella Attenuated Live Vaccine Industry Drivers
2.3 Varicella Attenuated Live Vaccine Industry Opportunities and Challenges
2.4 Varicella Attenuated Live Vaccine Industry Restraints
3 Varicella Attenuated Live Vaccine Market by Manufacturers
3.1 Global Varicella Attenuated Live Vaccine Revenue by Manufacturers (2020-2025)
3.2 Global Varicella Attenuated Live Vaccine Sales by Manufacturers (2020-2025)
3.3 Global Varicella Attenuated Live Vaccine Average Sales Price by Manufacturers (2020-2025)
3.4 Global Varicella Attenuated Live Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Varicella Attenuated Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Varicella Attenuated Live Vaccine Manufacturers, Product Type & Application
3.7 Global Varicella Attenuated Live Vaccine Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Varicella Attenuated Live Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Varicella Attenuated Live Vaccine Players Market Share by Revenue in 2024
3.8.3 2024 Varicella Attenuated Live Vaccine Tier 1, Tier 2, and Tier 3
4 Varicella Attenuated Live Vaccine Market by Type
4.1 Varicella Attenuated Live Vaccine Type Introduction
4.1.1 Monovalent Vaccine
4.1.2 Combination Vaccine
4.2 Global Varicella Attenuated Live Vaccine Sales by Type
4.2.1 Global Varicella Attenuated Live Vaccine Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Varicella Attenuated Live Vaccine Sales by Type (2020-2031)
4.2.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2031)
4.3 Global Varicella Attenuated Live Vaccine Revenue by Type
4.3.1 Global Varicella Attenuated Live Vaccine Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2020-2031)
4.3.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2020-2031)
5 Varicella Attenuated Live Vaccine Market by Application
5.1 Varicella Attenuated Live Vaccine Application Introduction
5.1.1 Kids Injection
5.1.2 Adults Injection
5.2 Global Varicella Attenuated Live Vaccine Sales by Application
5.2.1 Global Varicella Attenuated Live Vaccine Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Varicella Attenuated Live Vaccine Sales by Application (2020-2031)
5.2.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2031)
5.3 Global Varicella Attenuated Live Vaccine Revenue by Application
5.3.1 Global Varicella Attenuated Live Vaccine Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2020-2031)
5.3.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2020-2031)
6 Global Varicella Attenuated Live Vaccine Sales by Region
6.1 Global Varicella Attenuated Live Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Varicella Attenuated Live Vaccine Sales by Region (2020-2031)
6.2.1 Global Varicella Attenuated Live Vaccine Sales by Region (2020-2025)
6.2.2 Global Varicella Attenuated Live Vaccine Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Varicella Attenuated Live Vaccine Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Varicella Attenuated Live Vaccine Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Varicella Attenuated Live Vaccine Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Varicella Attenuated Live Vaccine Revenue by Region
7.1 Global Varicella Attenuated Live Vaccine Revenue by Region
7.1.1 Global Varicella Attenuated Live Vaccine Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Varicella Attenuated Live Vaccine Revenue by Region (2020-2025)
7.1.3 Global Varicella Attenuated Live Vaccine Revenue by Region (2026-2031)
7.1.4 Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Varicella Attenuated Live Vaccine Revenue (2020-2031)
7.2.2 North America Varicella Attenuated Live Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Varicella Attenuated Live Vaccine Revenue (2020-2031)
7.3.2 Europe Varicella Attenuated Live Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Varicella Attenuated Live Vaccine Revenue (2020-2031)
7.4.2 Asia-Pacific Varicella Attenuated Live Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Varicella Attenuated Live Vaccine Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Varicella Attenuated Live Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Merck
8.1.1 Merck Comapny Information
8.1.2 Merck Business Overview
8.1.3 Merck Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Merck Varicella Attenuated Live Vaccine Product Portfolio
8.1.5 Merck Recent Developments
8.2 BCHT
8.2.1 BCHT Comapny Information
8.2.2 BCHT Business Overview
8.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 BCHT Varicella Attenuated Live Vaccine Product Portfolio
8.2.5 BCHT Recent Developments
8.3 Shanghai Institute
8.3.1 Shanghai Institute Comapny Information
8.3.2 Shanghai Institute Business Overview
8.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio
8.3.5 Shanghai Institute Recent Developments
8.4 GSK
8.4.1 GSK Comapny Information
8.4.2 GSK Business Overview
8.4.3 GSK Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 GSK Varicella Attenuated Live Vaccine Product Portfolio
8.4.5 GSK Recent Developments
8.5 Keygen
8.5.1 Keygen Comapny Information
8.5.2 Keygen Business Overview
8.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Keygen Varicella Attenuated Live Vaccine Product Portfolio
8.5.5 Keygen Recent Developments
8.6 Green Cross
8.6.1 Green Cross Comapny Information
8.6.2 Green Cross Business Overview
8.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Green Cross Varicella Attenuated Live Vaccine Product Portfolio
8.6.5 Green Cross Recent Developments
8.7 Biken
8.7.1 Biken Comapny Information
8.7.2 Biken Business Overview
8.7.3 Biken Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Biken Varicella Attenuated Live Vaccine Product Portfolio
8.7.5 Biken Recent Developments
8.8 Shanghai Rongsheng Biotech
8.8.1 Shanghai Rongsheng Biotech Comapny Information
8.8.2 Shanghai Rongsheng Biotech Business Overview
8.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio
8.8.5 Shanghai Rongsheng Biotech Recent Developments
8.9 Changchun Changsheng Life Sciences Limited
8.9.1 Changchun Changsheng Life Sciences Limited Comapny Information
8.9.2 Changchun Changsheng Life Sciences Limited Business Overview
8.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio
8.9.5 Changchun Changsheng Life Sciences Limited Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Varicella Attenuated Live Vaccine Value Chain Analysis
9.1.1 Varicella Attenuated Live Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Varicella Attenuated Live Vaccine Production Mode & Process
9.2 Varicella Attenuated Live Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Varicella Attenuated Live Vaccine Distributors
9.2.3 Varicella Attenuated Live Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings